(NASDAQ: BDSX) Biodesix's forecast annual revenue growth rate of 21.58% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 9.46%, and it is also forecast to beat the US market's average forecast revenue growth rate of 15.37%.
Biodesix's revenue in 2026 is $88,499,000.On average, 7 Wall Street analysts forecast BDSX's revenue for 2026 to be $1,076,138,359, with the lowest BDSX revenue forecast at $1,005,749,683, and the highest BDSX revenue forecast at $1,128,289,073. On average, 7 Wall Street analysts forecast BDSX's revenue for 2027 to be $1,284,149,713, with the lowest BDSX revenue forecast at $1,185,467,550, and the highest BDSX revenue forecast at $1,351,876,633.
In 2028, BDSX is forecast to generate $1,510,891,947 in revenue, with the lowest revenue forecast at $1,411,519,698 and the highest revenue forecast at $1,598,236,999.